FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class
The FDA review extensions for JAK inhibitors are stacking up.
After Eli Lilly and Incyte disclosed late Tuesday that their supplemental NDA for Olumiant in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
